Aaron R. Hansen

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Tumour heterogeneity in the clinic

Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain et al. · Nature · 2013 · 1.2K citations · Full text

Neuro-oncology, Tumoral Pathology, Tumor Heterogeneity +5

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies

Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno et al. · International Journal of Cancer · 2020 · 485 citations · Full text

Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla et al. · Nature Cancer · 2020 · 466 citations

Prognostic Biomarkers, Tumor Dna Analysis, Medicine +11